{
    "nctId": "NCT06288620",
    "briefTitle": "Microwave Ablation in the Treatment of Early-stage Unifocal Invasive Breast Cancer",
    "officialTitle": "A Prospective, Open-label, Single-arm Phase II Clinical Study to Evaluate the Efficacy and Safety of Microwave Ablation in the Treatment of Early-stage Unifocal Invasive Breast Cancer",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 77,
    "primaryOutcomeMeasure": "Complete ablation rate",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. female patients aged 18-70 years;\n2. patients with newly diagnosed invasive breast cancer confirmed by core needle biopsy;\n3. the tumor smaller than 2cm in greatest diameter confirmed by US (ultrasonography), breast X-ray and breast MRI (contrast-enhanced magnetic resonance image ) were performed at the same time, and the difference of the largest diameter between breast US and MRI was less than 0.5 cm;\n4. the single tumor without other suspicious lesions (BI-RADS (the Breast Imaging Recording and Data System) score \u22654) evaluated by breast US, X-ray and MRI;\n5. the tumor without adhesion to chest wall, nipple or skin;\n6. patients without distant metastasis;\n7. Karnofsky performance status greater than 70%.\n\nExclusion Criteria:\n\n1. multicentric or multifocal breast tumor;\n2. the tumor located on nipple and areola area;\n3. signs of extensive intraductal carcinoma on imaging examination (diffuse malignant calcification on breast X-ray or segmental distribution, non-mass enhancement, ductal or linear enhancement \\> 2.5 cm on MRI);\n4. extensive intraductal component in invasive cancer (more than 50% of the tumor volume) confirmed by pathology;\n5. invasive lobular carcinoma, metaplastic carcinoma or carcinoma with sclerosing adenosis;\n6. patients who were pregnant or breastfeeding;\n7. patients with evidence of coagulopathy, chronic liver diseases or renal failure;\n8. patients with previous treatment including chemotherapy, targeted drug therapy, or local radiation therapy, etc;\n9. patients with substance abuse, or mental or psychological disorders that may interfere with study compliance;\n10. any condition that is unstable or likely to compromise the patient's safety and compliance;\n11. patients enrolled in other clinical trials;\n12. diseases or symptoms that other investigators consider unsuitable for participation.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}